Evaluation of Local Anlagesia Into the Trocar Site During Operative Laparosocpy
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
In the literature there is conflicting data on administration of local analgesia in addition to the general anesthesia to the trocar sites during laparoscopy, We believe that adding local analgesia to the general anesthesia during laparoscopy is beneficial . the current study will evaluate prospectivly the impact of local analgesia on postoperative pain and recovery in patients undergoing operative laparoscopy
| Condition | Intervention |
|---|---|
|
Pain |
Drug: bupivacain 0.5% |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Evaluation of Local Anlagesia Into the Trocar Site During Operative Laparosocpy |
- postoperative pain measured by VAS [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
- total analgesics required, patient recovery, patient satisfaction [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 120 |
| Study Start Date: | September 2010 |
| Estimated Study Completion Date: | September 2011 |
| Estimated Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
preemptive trocar site analgesia
|
Drug: bupivacain 0.5%
trocar site injection
Other Name: marcaine
|
|
Experimental: 2
trocar site pre skin closure analgesia
|
Drug: bupivacain 0.5%
trocar site injection
Other Name: marcaine
|
|
No Intervention: 3
control
|
Detailed Description:
Methods: this is a blinded prospective randomized study. After approval of IRB and informed consent 120 patients undergoing for laparoscopy will be randomized after the induction of general anesthesia into three groups: Group A will receive preemptive analgesia using 3-5 cc of 0,5 % marcaine at the beginning of the procedure. Group 2 will receive a local analgesia using 3-5 cc marcaine at the end of the procedure. Group 3 will be operated under general anesthesia only. The post operative pain and patient recovery will be assessed by the nurses during the hospitalization using a VAS (Visual Analog Scale) the total analgetic drugs will be noted and after the patients discharge the patient status and satisfaction will be evaluated by phone up to 2 wks
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Female older then 18 y/o
Exclusion Criteria:
- Allergy to marcaine
Contacts and Locations| Contact: Ilan atlas, md | 011972506267421 | ilanatlas@yahoo.com |
| Contact: samer tannus, md | 01197249540410 | stannus@bezeqint.net |
| Israel | |
| Poria Gov Hospital | Not yet recruiting |
| Tiberias, Lower Galilee, Israel, 15208 | |
| Contact: ilan Atlas, MD 01197249080914 ilanatlas@yahoo.com | |
| Contact: Samer Tannus, MD 01197246652565 stannus@bezeqint.co.il | |
| Principal Investigator: Ilan Atlas, MD | |
| Study Chair: | Ilan Atlas, MD | Ministry of Health, Israel |
More Information
No publications provided
| Responsible Party: | Ilan Atlas, MD Gynecologic Oncology Director, Poria Medical Center |
| ClinicalTrials.gov Identifier: | NCT00728559 History of Changes |
| Other Study ID Numbers: | lapmar1.CTIL |
| Study First Received: | August 1, 2008 |
| Last Updated: | February 2, 2011 |
| Health Authority: | Israel: Ministry of Health |
Keywords provided by The Baruch Padeh Medical Center, Poriya:
|
laparoscopy preemptive postoperative |
pain trocar site |
Additional relevant MeSH terms:
|
Bupivacaine Anesthetics, Local Anesthetics Central Nervous System Depressants Physiological Effects of Drugs |
Pharmacologic Actions Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 16, 2013